Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

KURA

Phase 1b

Ziftomenib + venetoclax/azacitidine (ven/aza) or cytarabine/daunorubicin (7+3)

AML (Acute Myeloid Leukemia) (NPM1-m and KMT2A-r)

Q2 2025

KOMET-007 trial. 1/30/24- Initial data from 20 patients. Enrollment at 400 mg dose ongoing. 12/9/24- Interim data reported and presented at ASH '24. 2/26/25- Present prelim data at a medical meeting in Q2 2025.

Data readout

INMB

Phase 2

XPro1595 (XPro™)

AD (Alzheimer’s Disease)

Q2 2025

AD02 trial. 1/30/24- Ph2 clinical hold lifted in US. 11/13/24- Dosed first patients in Ph2 trial. Topline cognitive results in Q2 2025.

Data readout

NKTR

Phase 2

NKTR-255 + Avelumab

UC (Urothelial carcinoma)

H1 2025

JAVELIN Bladder Medley study. 3/12/25- Trial ongoing w/ top-line data in H1 2025.

Data readout

EWTX

Phase 2

Sevasemten (EDG-5506)

DMD (Duchenne Muscular Dystrophy)

H1 2025

LYNX trial. Initiated on 10/27/22. 11/30/23- Received FDA ODD. 5/16/24- Data in Q4 2024. 3/3/25- Report data in H1 2025.

Data readout

TRML

Phase 2b

Pacibekitug (TOUR006)

Thyroid Eye Disease

H2 2025

spiriTED trial. 3/13/25- Trial ongoing. Topline data in H2 2025.

Data Readout

PTCT

Phase 2

PTC518

HD (Huntington's Disease)

Q2 2025

PIVOT-HD trial. 6/21/23- Interim data and all objectives met from the 12wk trial period. Enrollment ongoing. 6/20/24- Interim results, FDA lifts partial clinical hold. 9/26/24 Fast Track Designation. 2/27/25- 12mt results in Q2 2025.

Data readout

ASMB

Phase 1b

ABI-4334

HBV (Hepatitis B virus)

H1 2025

11/08/23- Ph1a completed. 8/8/24- Dosing initiated. 12/26/24- 150mg dose showed strong antiviral activity. Enrollment for 400 mg cohort ongoing. 3/20/25- Safety, efficacy, and PK data in H1 2025.

Data readout

NKTR

Phase 2b

Rezpegaldesleukin (NKTR-358)

Moderate-to-Severe Atopic Dermatitis (AD)

H1 2025

REZOLVE-AD trial. 11/2023- Trial initiated. 1/10/25- Target enrollment reached. 2/10/25- FDA Fast Track Designation. 3/12/25- Topline data in H1 2025.

Data readout

MURA

Phase 2

Nemvaleukin alfa +/- pembrolizumab

Advanced cutaneous melanoma/ Advanced mucosal melanoma

Q2 2025

ARTISTRY-6. 11/22/24- Topline data from cohort 2 in Q2 2025, cohort 3 in H1 2025 and cohort 4 in H2 2025.

Data readout

ATAI

Phase 3

COMP360

TRD (Treatment-resistant depression)

Q2 2025

Big Mover: w/ COMPASS Pathways. COMP005, COMP006 trials. 2/29/24- COMP005 top-line data in H2 2024, COMP006 on track for top-line data in mid-2025.

Data Readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20